The Lancet: New treatment for multiple myeloma increases lifetime by 47%

▌ nuclear output inhibitors: Selinexor Selinexor is an oral selective nuclear output inhibitor.
So far, Selinexor has been approved for two tumor adaptations in the U.S.: Last July, Selinexor was approved by the U.S. FDA to treat adult recurring/refractic multiple myeloma patients who have previously received at least four treatments, including at least two protease inhibitors, at least two immunomodulants, and anti-CD38 monoclonal antibodies.
June, Selinexor was approved by the FDA to treat adult patients with recurring/refractic diffuse large B-cell lymphoma (DLBCL) who had received at least 2 lines of treatment in the past, including DLCBL caused by folytic lymphoma.
addition, Selinexor's application for a new supplement for the treatment of multiple myeloma (sNDA) has been submitted and the FDA expects to respond with approval in March next year.
approved, it will be a powerful complement to existing treatment options for patients with relapsed/resusable multiple myeloma.
, Selinexor is currently conducting a number of clinical trials, including liposarcoma and endometrial cancer.
▌ progress-free life is significantly improved, and patients benefit from the new program! The published results of the Phase 3 BOSTON study, conducted in more than 150 clinical locations around the world, included 402 adult patients with relapsed or resuscable multiple myeloma who had received one or three treatments in the past.
previous study, the highest percentage (about 50%) of patients with high-risk cytogenetics in the study.
study aims to compare the efficacy, safety and health-related quality of life parameters of SVd and current standard therapy Vd.
end point is progression-free lifetime (PFS), and the key secondary endpoints include overall mitigation rate (ORR), peripheral neuropathy rate, etc.
results showed that the progress-free survival of the SVd treatment group increased by 47% compared to the Vd group! The mid-PFS increased by 4.47 months (13.93 months VS 9.46 months).
the total mitigation rate of the SVd group increased significantly compared to the Vd group, reaching 76.4% (VS 62.3%).
, patients in the SVd group who had previously received only one treatment had a higher ORR (80.8% VS 65.7%).
Importantly, the SVd program showed consistent PFS benefits and higher ORR in several important subgroups, including patients over 65 years of age, patients at high risk of cytogenetics, moderate renal insemination, and patients who had been treated with boronazome or lysolamine.
the SVd treatment group showed higher depth remission rates (very good partial remission) (44.6% VS 32.4%) and longer medium remission times (20.3 months VS 12.9 months) compared to the Vd group.
16.9 per cent of patients in the SVd group received complete remission, while only 10.6 per cent of patients treated with Vd were treated.
-term data show that the SVd treatment group has not yet reached the OS median, but the number of deaths is low (47 VS 62), showing an overall trend of benefit.
, the rate of peripheral neuropathy (PN) in the SVd group was significantly lower (32.3 percent to 47.1 percent) compared to the Vd group.
the SVd ≥ also significantly reduced level 2 PN rate (21% VS 34.3%).